GeneDx

The models drive interpretation, and sequencing and expert review remain load bearing. GeneDx describes its interpretation as automation, bioinformatics and cloud-based machine learning run with a human in the loop, over the GeneDx Infinity dataset of prior cases. One component is published: Multiscore, a random forest classifier that ranks the genes carrying a patient's variants by how well they fit the patient's clinical features, so that analysts review the likeliest candidates first.

The company also acquired Fabric Genomics, an AI interpretation software company. The test itself is exome or genome sequencing in the company's own laboratory, reviewed and signed out by its clinical scientists, so the model narrows and orders the work rather than producing the diagnosis alone.

The oversight structure is described and part of it is missing. Tests are ordered by licensed providers, including, since August 2026, clinicians in an online network that families reach through GeneDx.com. In the laboratory, genotype filters reduce a case to the genes with variants that need review (an average of 173 in the Multiscore study), Multiscore ranks them by fit with the patient's clinical features, and clinical scientists review the ranked list before a report is signed out; the company describes this as human in the loop. Reanalysis is offered at no extra charge.

What is not described is how far down the ranked list a reviewer goes, what a reviewer sees about genes the filters removed, what confidence accompanies the ranking, or what triggers reanalysis. The online ordering network's clinicians are not named, and how they are independent of the laboratory is not stated.

One model is described in the literature and the rest are named only as a category. Multiscore (Human Genetics, 2026) combines similarity subscores between a patient's clinical features and gene-phenotype associations drawn from OMIM, the literature and GeneDx clinical data, and feeds them to a random forest classifier that ranks candidate genes; it handles inexact phenotype terms from real clinical notes and prioritized 74 genes with no OMIM entry. The annual report describes automation, bioinformatics and cloud-based machine learning more broadly, and the acquisition of Fabric Genomics adds AI interpretation software.

What is not published is the version history of Multiscore or the wider pipeline, how a change is validated, and how a report records the pipeline version that produced it, which matters because the same sequence can be classified differently as the dataset grows.

The models are in-house, and the data leaves in other directions. Multiscore and the interpretation pipeline are GeneDx's own, and Fabric Genomics is now part of the company, so no outside model provider sits in the interpretation chain on what is published. The parties that are disclosed are elsewhere: unnamed third party cloud storage and workflow providers that hold nearly all data storage and analytics, unnamed clinicians in the online ordering network, research collaborators, and third parties that may receive collated de-identified variant data for commercial purposes, with GeneDx compensated.

No subprocessor list, cloud provider name or list of commercial data recipients is published.

Prospective, academically led evidence in the intended setting, with a guideline behind the modality. SeqFirst-neo (American Journal of Human Genetics, 2025), run by the University of Washington and Seattle Children's using GeneDx rapid genome sequencing, assessed all 408 NICU admissions from January 2021 to February 2022; of 240 eligible infants, 126 offered testing had a precise genetic diagnosis in 49.2 percent, against 9.7 percent of 114 in conventional care, a difference that held at 12 months, and a standard eligibility workflow would have missed 42 percent of those diagnoses. Boston Children's Hospital investigators, with GeneDx co-authors, reported diagnoses from reanalysis at scale (HGG Advances, 2026), and the company's Multiscore ranking model was evaluated on 9,989 cases (Human Genetics, 2026). The American Academy of Pediatrics recommends exome or genome sequencing as a first-tier test for children with global developmental delay or intellectual disability.

The company's own diagnostic rate figures on its billing page (for example, 40 to 50 percent for rapid genome testing) are cited to studies rather than to its full volume.

The commercial use of patient data is disclosed plainly, with retention left open-ended. The privacy policy says GeneDx creates de-identified and aggregated data from personal information, that research discoveries may have commercial value and be owned by GeneDx or its collaborators, and that de-identified variant data may be collated and sent to third parties for research or commercial purposes, for which GeneDx may be compensated; research sharing follows the person's consent. Personal information is kept as long as necessary for its purposes, and a person can ask for deletion, subject to legal and contractual holds. The HIPAA notice allows research use when reviewed by an institutional review board or privacy board, and the Multiscore study was run on de-identified data under an IRB waiver of consent.

The open question is what de-identification achieves for rare disease genomes, where an unusual phenotype and variant can point to one family, and parental samples in trio testing bring relatives into the dataset. No retention period for specimens, raw sequence or variant calls is published, and safety engineering for the interpretation models is not described.

Covered entity status is stated and a substantive privacy document reaches the patient; no contracting instrument is published. GeneDx's HIPAA notice of privacy practices applies to the PHI it creates or keeps as a covered entity (part of an affiliated covered entity whose members are available on request) and covers treatment, payment and operations uses, research under IRB or privacy board review, and patient rights. The privacy policy ties research sharing to the person's consent and discloses commercial transfer of de-identified data.

The company publishes no agreement for ordering institutions, no business associate terms for the online ordering network or cloud providers, and no subcontractor provisions, so the terms governing what flows back into a health system's records sit in contracts that are not public.

An outside check is described without an attestation. The annual report (Item 1C) says the company assesses cyber risk regularly, monitors and tests its systems, works with third party cybersecurity assessors and consultants to evaluate its prevention and response, runs due diligence on third parties, and has a Chief Information Security Officer reporting through an enterprise risk committee to the audit committee.

The licenses and certifications page lists laboratory credentials (CLIA, CAP and state licenses for Maryland, Rhode Island, California, Pennsylvania and New York), which cover testing quality rather than information security. No SOC 2, HITRUST or ISO/IEC 27001 attestation is named, for a company holding genomic data from millions of tests that cannot be reissued if exposed.

A Breakthrough designation stated as a designation, with no submission described. The annual report says FDA granted Breakthrough Device Designation in October 2025 for ExomeDx and GenomeDx for analysis of DNA from blood in pediatric and adult patients with unexplained constitutional or heritable disorders, including rapid neonatal testing in critical care; the tests are offered today as laboratory developed tests, and the company notes that its tests may only be ordered by authorized healthcare providers. No premarket submission or timeline is disclosed. The laboratory holds CLIA, CAP and state licenses, including New York approval for tests marked as such, with single-use permits handled for others.

Results within the group most at risk are published, and the cross-group comparison of interpretation is not. Variant interpretation leans on reference data drawn mostly from people of European ancestry, so patients of other ancestries receive uncertain results more often. SeqFirst-neo (Wenger et al., American Journal of Human Genetics 2025), run by the University of Washington and Seattle Children's with GeneDx scientists as co-authors and GeneDx rapid genome sequencing, offered testing to 126 of 240 eligible NICU infants and reported a precise genetic diagnosis in 49.2 percent, against 9.7 percent under conventional care; among non-White infants the figures were 45.9 and 20.7 percent, and neonatologists were less able to predict which non-White infants would receive a diagnosis.

What is not published is diagnostic yield and the rate of uncertain results by ancestry across GeneDx's own testing volume, or how the Infinity dataset's growth is closing that gap. No AI governance framework for the interpretation models is published.

An error rate for the ranking model is published with its denominator, and a correction route exists; nothing makes the company answerable for a result. In the Multiscore evaluation (Human Genetics, 2026; 9,989 exome and genome cases), genotype filtering left an average of 173 genes for review, and the reported diagnostic gene ranked first in 33 percent of cases, in the top 5 in 69 percent, the top 10 in 83 percent and the top 20 in 93 percent, so in about 7 percent of solved cases the answer sat below the top 20. The provider billing page lists reanalysis at no extra charge for exome and genome tests, which gives a family a route back when knowledge changes.

No guarantee, indemnity or remediation obligation attaches to a report, and how pipeline versions are recorded against issued reports is not published.

A named bidirectional integration with a major record system, running in production. Through Epic Aura, health systems order GeneDx exome, genome and rapid genome tests inside Epic and receive results back as structured, discrete data alongside other laboratory results; UNC Health went live first when the integration launched in February 2025, and its pediatric geneticist describes results sitting with other lab results rather than in a separate section. In August 2026 GeneDx added Exome-to-Genome Reflex ordering inside Epic Aura, and the integration page links release notes for Aura updates.

What remains for a buyer is whether reclassified variants flow back into the record as updated discrete results, and which record systems other than Epic are supported.

A single hosted service with the location implied rather than committed. Testing runs in the company's accredited laboratory in Gaithersburg, Maryland, and the annual report says nearly all data storage and analytics run on third party cloud storage and workflow providers, whom it does not name; it also describes plans for cloud-based interpretation services that let partners sequence locally and send data for analysis, in part to meet local restrictions.

No provider, region, residency commitment, tenancy model or retention period for raw sequence and variant calls is published, and how the clinical pipeline is separated from the research and commercial dataset is not described.

No price is published and the posture is discoverable. Tests can be billed to the patient's insurance, to an institutional account or to the patient as self-pay; GeneDx accepts commercial insurance, Medicaid, Medicare and Tricare and is in network with many plans, supports prior authorization, and offers financial assistance, sponsored testing programs and interest-free payment plans. The billing page explains what drives the cost (test type, coverage, prior authorization, deductible, billing option) and lists reanalysis at no extra charge. The 2026 annual physician notice sets out ordering and billing policies.

No list price, self-pay rate or institutional rate is published, including for the online family ordering route launched in August 2026.

Settings and specialties are named test by test, with validation behind them. The site organizes testing by specialty (general pediatrics, pediatric neurology, genetics, maternal-fetal medicine) and clinical area (autism, cerebral palsy, congenital heart disease, epilepsy, developmental delay and intellectual disability, inborn errors of immunity, NICU and PICU), with ultraRapid genome sequencing for critical care, prenatal genome testing for pregnancies with fetal anomalies, and newborn screening through the NIH BEACONS program.

The NICU use is supported by the SeqFirst-neo trial, the pediatric outpatient use by the American Academy of Pediatrics first-tier recommendation, and the online family route opened in August 2026 is limited to children with developmental delay, intellectual disability or epilepsy, subject to clinical appropriateness and state rules.